Philips and Microsoft Collaborate on Augmented Reality Concept for Azurion Image-Guided Therapies


February 24, 2019—Royal Philips announced the introduction of a mixed reality concept that combines the company's Azurion image-guided therapy platform and Microsoft’s HoloLens 2 holographic computing platform, allowing augmented reality applications for image-guided minimally invasive therapies.

Philips and Microsoft unveiled the technology at MWC Barcelona (formerly Mobile World Congress), held February 25–28 in Barcelona, Spain.

According to Philips, the augmented reality concept is built for Microsoft's HoloLens 2 and brings live imaging and other sources of vital data currently displayed on large two-dimensional screens into a three-dimensional holographic augmented reality environment that can be controlled by the physician. The concept is being used to gather further clinical insights to support the development of future commercially available augmented reality solutions for use in image-guided procedures.

Microsoft unveiled HoloLens 2 at MWC Barcelona. HoloLens is a self-contained holographic computer that enables hands-free, heads-up interaction with three-dimensional digital objects. The technology is complemented by existing and new Microsoft Azure cloud services and has built-in artificial intelligence.

The Azurion platform is powered by Philips’ ConnectOS, which allows the integration of advanced digital innovations on the platform, advised the company.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.